Today: 7 February 2026
Subscribe
Browse Category

Medical Technology News 13 January 2026 - 23 January 2026

Intuitive Surgical stock jumps premarket after earnings beat, but 2026 tariff hit gets attention

Intuitive Surgical stock jumps premarket after earnings beat, but 2026 tariff hit gets attention

New York, Jan 23, 2026, 05:30 EST — Premarket Intuitive Surgical shares climbed $19.19 to $545 in premarket trading Friday, following a 3.3% gain in after-hours trading after the company topped fourth-quarter estimates. (Public) This shift is significant since Intuitive’s earnings typically serve as a barometer for the wider surgical-robotics sector, where investors are keen to gauge procedure demand, hospital capital outlays, and what comes after a robust 2025. Tariffs are starting to weigh on medtech firms with global supply chains. Intuitive now faces the challenge of pinpointing how this will impact profit margins by 2026. During the quarter, global
23 January 2026
····
Intuitive Surgical stock whipsaws after Q4 beat as 2026 da Vinci outlook and tariffs hit focus

Intuitive Surgical stock whipsaws after Q4 beat as 2026 da Vinci outlook and tariffs hit focus

NEW YORK, Jan 22, 2026, 19:45 EST — After-hours Intuitive Surgical shares edged up about 0.4% to $525.81 in volatile after-hours trading Thursday, following a quarterly earnings report that topped Wall Street’s profit and revenue forecasts. The stock fluctuated between $511.73 and $548 as investors digested a 2026 outlook that includes higher tariff expenses—a key concern for a company manufacturing most of its da Vinci instruments and accessories in Mexico. (Reuters) This shift is significant since Intuitive’s “procedure growth”—the tally of surgeries done with its robots—offers a quick snapshot of hospital demand. It also drives the company’s steady stream of
23 January 2026
·····
Intuitive Surgical Q4 2025 earnings beat lifts ISRG, but 2026 da Vinci forecast slows on tariffs

Intuitive Surgical Q4 2025 earnings beat lifts ISRG, but 2026 da Vinci forecast slows on tariffs

SUNNYVALE, Calif., Jan 22, 2026, 13:58 PST Intuitive Surgical topped Wall Street forecasts for Q4 profit and revenue on Thursday, buoyed by steady demand for its da Vinci surgical robots. The news pushed shares 3.3% higher in after-hours trading. (Reuters) Investors are shifting their attention from quarterly sales to procedure growth — the count of surgeries performed using the robots — since that fuels repeat sales of instruments, accessories, and service. Hospitals are still clearing backlogs of postponed care, raising the question of how sustainable that demand will be amid tightening budgets and growing competition. (Reuters) In a recent SEC
22 January 2026
·····
Intuitive Surgical stock ticks up ahead of earnings after a bruising slide — what traders watch next

Intuitive Surgical stock ticks up ahead of earnings after a bruising slide — what traders watch next

New York, January 22, 2026, 14:36 ET — Trading session ongoing Intuitive Surgical shares jumped 0.9% to $528.38 Thursday, clawing back after a recent dip that had the surgical-robot maker trailing some peers in the medtech sector. Medtronic gained roughly 1.0%, while Stryker edged down 0.6%. The shift happens just hours ahead of Intuitive’s fourth-quarter results, set to drop after markets close. Investors want clearer signals on demand, especially after last week’s update shook confidence in 2026 growth projections. Intuitive dropped 1.4% on Tuesday, marking its sixth day in a row of declines. The stock remains roughly 14% under its
22 January 2026
·····
Abbott (ABT) stock price ticks higher as heart-device news lands ahead of earnings — what investors watch

Abbott (ABT) stock price ticks higher as heart-device news lands ahead of earnings — what investors watch

New York, Jan 21, 2026, 13:17 EST — Regular session Shares of Abbott Laboratories ticked up 0.2% to $121.34 on Wednesday, trimming earlier volatility as traders braced for the company’s upcoming quarterly earnings report. Timing is key. Abbott is set to report before Thursday’s opening bell, as traders eye new guidance for 2026 following a flurry of device news over the past day. Abbott grabbed attention with news of fresh European clearance for an ablation catheter designed for heart-rhythm procedures, alongside a distinct partnership targeting a next-gen defibrillator implant. Abbott trailed behind despite healthcare’s overall strength: the Health Care Select
21 January 2026
·····
Intuitive Surgical stock slips as ISRG heads into key earnings call after softer 2026 outlook

Intuitive Surgical stock slips as ISRG heads into key earnings call after softer 2026 outlook

New York, Jan 20, 2026, 2:03 PM EST — Regular session Intuitive Surgical (ISRG.O) dipped roughly 1.5% to $526.76 in Tuesday afternoon trading, as U.S. stocks slipped broadly. The S&P 500 ETF dropped about 1.9%, and the Nasdaq 100 ETF lost close to 1.9%, though the healthcare sector showed much smaller declines. Intuitive Surgical shares remain in the spotlight as the company prepares to report quarterly results later this week, following management’s warning of slower growth in a crucial demand indicator. That metric is “procedures” — the count of surgeries done with Intuitive’s da Vinci robots. It’s crucial since procedures
20 January 2026
·····
Intuitive Surgical stock (ISRG) heads into earnings week after Friday drop — what to watch next

Intuitive Surgical stock (ISRG) heads into earnings week after Friday drop — what to watch next

New York, Jan 17, 2026, 16:53 EST — Market closed. Intuitive Surgical (ISRG.O) shares closed Friday down 1.2% at $535, marking a fifth straight session of losses as volume outpaced recent averages. The stock traded in a range from $532.63 to $542.99 during the day, while medtech peers showed mixed results. (MarketWatch) U.S. stock markets were closed Monday for Martin Luther King Jr. Day, leaving investors to start a shortened week still digesting recent figures from the surgical-robot maker. Trading picks up again Tuesday. (New York Stock Exchange) The immediate focus is on pace, not only the dollar amounts. Intuitive’s
17 January 2026
·····
Intuitive Surgical stock slips again as 2026 da Vinci outlook hangs over ISRG ahead of earnings

Intuitive Surgical stock slips again as 2026 da Vinci outlook hangs over ISRG ahead of earnings

New York, Jan 16, 2026, 13:19 EST — Regular session Intuitive Surgical shares slid on Friday, extending a pullback that followed the company’s softer-than-expected outlook for growth in procedures on its flagship da Vinci surgical robots. The stock was down 0.9% at $536.49 in early afternoon trading. The near-term focus is procedure growth — the number of operations done using Intuitive’s systems — because it feeds demand for the company’s instruments and accessories, the higher-frequency part of its business. That matters now because the company’s latest range for 2026 da Vinci procedure growth came in below what some investors had
16 January 2026
·····
Intuitive Surgical stock slips again as 2026 da Vinci outlook keeps pressure on ISRG

Intuitive Surgical stock slips again as 2026 da Vinci outlook keeps pressure on ISRG

New York, January 15, 2026, 12:06 (EST) — Regular session Intuitive Surgical shares dropped once more on Thursday, continuing a selloff sparked by the company’s weaker growth forecast for procedures involving its da Vinci surgical robot. The stock slipped roughly 1% to $541.08 in midday trading, following a 2.7% drop on Wednesday. The procedure forecast is crucial because every da Vinci surgery drives repeat sales — the single-use instruments and accessories hospitals need for each operation. If that volume dips, the growth story shrinks, even if robot deliveries remain steady. Investors are weighing how quickly Intuitive can roll out its
15 January 2026
·····
Intuitive Surgical (ISRG) stock drops after 2026 da Vinci outlook flags slower growth

Intuitive Surgical (ISRG) stock drops after 2026 da Vinci outlook flags slower growth

New York, Jan 14, 2026, 17:40 (EST) — After-hours Shares of Intuitive Surgical dropped 2.7% to close at $546.76 on Wednesday, after the company projected slower growth in da Vinci procedures for 2026.Intuitive now expects procedure growth to hit roughly 13% to 15%. CEO Dave Rosa said they were “pleased with our strong performance” following a preliminary Q4 revenue report of $2.87 billion. (archive.fast-edgar.com) This procedure range is crucial because it offers the clearest glimpse investors have into demand for surgical robotics. Growth in procedures fuels the ongoing revenue streams — from instruments and accessories to service — rather than
15 January 2026
·····
TransMedics stock jumps as SEC filing details $23.9 million-a-year lease for new Massachusetts HQ

TransMedics stock jumps as SEC filing details $23.9 million-a-year lease for new Massachusetts HQ

New York, Jan 13, 2026, 12:08 EST — Regular session Shares of TransMedics Group climbed roughly 8% Tuesday following new disclosures about a long-term headquarters lease and land acquisitions next door in Massachusetts. The stock hit $151.70 during the session before pulling back to $145.68. This move is significant as it sets clear figures on a substantial, long-term expense just as investors demand concrete spending plans from medical device firms, not just promises. It also comes during J.P. Morgan Healthcare Conference week, a period when healthcare execs often tweak outlooks subtly, triggering market ripples. A recent regulatory filing revealed that
13 January 2026
·····
DexCom stock jumps in premarket after early Q4 sales and 2026 outlook; what DXCM investors watch next

DexCom stock jumps in premarket after early Q4 sales and 2026 outlook; what DXCM investors watch next

NEW YORK, Jan 13, 2026, 7:52 AM ET — Premarket DexCom shares climbed roughly 5% in premarket action Tuesday, buoyed by new guidance that thrust the diabetes-device company back into focus as earnings season kicks off. (StreetInsider.com) DexCom’s preliminary Q4 update offers investors an early glimpse at 2026 revenue growth, following a stretch where talk around guidance hurt the stock more than actual results. Shares tumbled sharply in late October after execs cautioned that 2026 growth might come in just under current forecasts. (Reuters) Tuesday’s action came amid a nervous market backdrop. U.S. stock index futures slipped slightly before the
13 January 2026
·····
1 2 3 4 … 6

Stock Market Today

Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

7 February 2026
Eli Lilly shares climbed 3.7% in after-hours trading after the FDA announced plans to restrict GLP-1 ingredients in unapproved compounded drugs. Hims & Hers shares dropped nearly 12% after being referred for a Justice Department probe. Investors are watching for details on enforcement and pricing pressure as the market reacts to moves against copycat obesity drugs.
IREN stock whipsaws after earnings as bitcoin rebounds; Microsoft GPU financing in focus

IREN stock whipsaws after earnings as bitcoin rebounds; Microsoft GPU financing in focus

7 February 2026
IREN Limited shares rose 5.1% to $41.83 in after-hours trading Friday as bitcoin jumped 11.4% to $71,198, lifting crypto-linked stocks. The company reported $184.7 million in quarterly revenue, with $167.4 million from bitcoin mining and $17.3 million from AI cloud services. Net loss reached $155.4 million. IREN recently announced $3.6 billion in GPU financing for a Microsoft contract and a new Oklahoma data center.
Netflix stock price rises after-hours as DOJ widens scrutiny of Warner deal

Netflix stock price rises after-hours as DOJ widens scrutiny of Warner deal

7 February 2026
The U.S. Justice Department is investigating Netflix’s business practices as part of its review of the proposed Warner Bros Discovery deal, the Wall Street Journal reported Friday. Netflix shares rose 1.6% to $82.20 in after-hours trading. Warner expects a shareholder vote on the deal in March. Paramount Skydance’s rival bid remains active.
Go toTop